GlyNAC

The reviewed dose-ranging trial found no detected primary-endpoint improvement over 14 days. Positive post-hoc subgroup findings need confirmation.

A change in a laboratory marker, a test score and everyday function are different outcomes. A statistically detectable result does not by itself tell us whether someone would notice a worthwhile difference.

Check the measured endpoint, comparison and study population. The full profile preserves effect estimates and the source's clinical-significance assessment, including when that assessment is not supplied.

The claim to test: A biochemical subgroup signal establishes a general longevity benefit.

What the reviewed records say:

The gap: Other trials, including the longer older-adult study, still require review. Clinical benefit and long-term safety remain unresolved.

Durability, effects in other populations and healthy-lifespan outcomes need their own evidence.

Independent replication, meaningful human outcomes, longer follow-up and better safety reporting would make these results easier to interpret.

Other trials, including the longer older-adult study, still require review. Clinical benefit and long-term safety remain unresolved.